OptimizeRx

OPRX

Market cap $141M

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m.

OptimizeRx (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data and technology company.

OptimizeRx's Q3 2025 results reinforce my long-term bullish thesis. OPRX demonstrates continued operational momentum, supporting confidence in sustained growth. Recent earnings solidify conviction in the company's strategic positioning and execution.

WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced four new partner agreements that meaningfully expand the Company's in-workflow point-of-care (POC) network, fortify its long-term competitive position, and increase total National Provider Identifier (NPI) reach.

ROKU, AVPT, ETOR, NRIM and OPRX have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2025.

OptimizeRx Corporation ( OPRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Stephen Silvestro - President & CEO Edward Stelmakh - Chief Financial & Strategic Officer Andrew D'Silva - Chief Business Officer Conference Call Participants Ryan Daniels - William Blair & Company L.L.C., Research Division Richard Baldry - ROTH Capital Partners, LLC, Research Division David Grossman - Stifel, Nicolaus & Company, Incorporated, Research Division Eric Martinuzzi - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B.

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.12 per share a year ago.

-   Q3 revenue of $26.1 million, increased 22% year-over-year-   Q3 gross profit increased 30% year-over-year to $17.5 million-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million-   Paid off an incremental $2 million in principal from term loan subsequent to the end of Q3 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended September 30, 2025.

WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call.